G. Pierce

发表

Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta.

M. Sporn, Thomas A. Mustoe, MD, FACS, G. Pierce, 1987, Science.

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

J. Rasko, M. Kay, J. Zehnder, 2006, Nature Medicine.

Mutations on the External Surfaces of Adeno-AssociatedVirus Type 2 Capsids That Affect Transduction andNeutralization

Shangzhen Zhou, P. Colosi, R. Surosky, 2006, Journal of Virology.

Platelet-derived growth factor induces phosphorylation of a 64-kDa nuclear protein.

G. Pierce, T. Deuel, L. Shawver, 1989, The Journal of biological chemistry.

Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo.

K. Longmuir, T. Ulich, G. Pierce, 1994, The Journal of clinical investigation.

Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB.

R. Allman, P. Goode, J. V. Vande Berg, 1994, The American journal of pathology.

Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.

J. Shendure, Martin Kircher, D. Aschman, 2017, Blood advances.

The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world

G. Pierce, D. Coffin, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use.

L. Chandler, G. Pierce, M. L. Phillips, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors.

M. Herlyn, M. Herlyn, T. Crombleholme, 2001, Human gene therapy.

FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation.

M. Herlyn, T. Crombleholme, L. Chandler, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project

B. Konkle, J. Johnsen, M. Skinner, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns

G. Pierce, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography.

J. F. Wright, J. F. Wright, J. Sommer, 2007, Journal of virological methods.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice

R. Blumberg, D. Lillicrap, N. Josephson, 2015, Cellular immunology.

In vivo incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins

Thomas A. Mustoe, MD, FACS, R. Senior, G. Griffin, 1988, The Journal of experimental medicine.

Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB.

J. Purdy, Thomas A. Mustoe, MD, FACS, G. Pierce, 1989, American journal of surgery.

Platelet-derived growth factor-BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds.

J. V. Vande Berg, Thomas A. Mustoe, MD, FACS, G. Pierce, 1991, The American journal of pathology.

Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model.

Thomas A. Mustoe, MD, FACS, C. Morishima, G. Pierce, 1991, The Journal of clinical investigation.

Differential regulation of the expression of proteinases/antiproteinases in fibroblasts. Effects of interleukin-1 and platelet-derived growth factor.

R. Strunk, G. Pierce, H. Welgus, 1991, The Journal of biological chemistry.

Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds.

W. Kenney, J. V. Vande Berg, M. Robson, 1995, The Journal of clinical investigation.

Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment

T. VandenDriessche, S. Pipe, D. Lillicrap, 2007, Journal of thrombosis and haemostasis : JTH.

Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation.

J. F. Wright, J. Sommer, G. Pierce, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

M. Ozelo, J. Sommer, K. High, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.

J. Dumont, Mingxuan Zhang, R. Kshirsagar, 2015, Biologicals : journal of the International Association of Biological Standardization.

Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein.

R. Virmani, A. Farb, Z. Parandoosh, 1997, Circulation research.

Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor

D. Danilenko, W. Kenney, G. Pierce, 1994, The Journal of experimental medicine.

Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor.

D. Danilenko, G. Pierce, J. Tarpley, 1995, The American journal of pathology.

Pharmacologic enhancement of wound healing.

Thomas A. Mustoe, MD, FACS, G. Pierce, 1995, Annual review of medicine.

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

J. Dumont, D. Quon, J. Sommer, 2012, Blood.

Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle.

L. Chandler, K. Blease, G. Pierce, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

AAV2-mediated gene delivery to monkey putamen: Evaluation of an infusion device and delivery parameters

Brian M. Suzuki, Kirk W. Johnson, J. Sommer, 2005, Experimental Neurology.

Macrophages: important physiologic and pathologic sources of polypeptide growth factors.

G. Pierce, 1990, American journal of respiratory cell and molecular biology.

Erratum: CORRIGENDUM: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

M. Kay, M. Ozelo, J. F. Wright, 2006 .

What is a cure and how do we get there?

M. Ozelo, D. Lillicrap, G. Pierce, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

J. Oldenburg, J. Mahlangu, R. Klamroth, 2016, Thrombosis and Haemostasis.

Growth factors and cytokines in hair follicle development and cycling: recent insights from animal models and the potentials for clinical therapy.

D. Danilenko, G. Pierce, D. M. Danilenko, 1996, Molecular medicine today.

Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia.

D. Danilenko, G. Pierce, C. Starnes, 1995, The American journal of pathology.

Management of COVID‐19‐associated coagulopathy in persons with haemophilia

C. Hermans, M. Makris, S. Pipe, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Mitogenic signals for platelet-derived growth factor isoforms in liver fat-storing cells.

G. Dubyak, W. Kenney, H. Abboud, 1991, The American journal of physiology.

Growth Factors and Wound Healing

D. Herndon, T. Ziegler, G. Pierce, 1997, Serono Symposia USA Norwell, Massachusetts.

Stem Cell Therapy in the Aging Hearts of Fisher 344 Rats: Synergistic Effects On

K. Horvath, G. Pierce, J. Doukas, 2005 .

Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging.

K. Horvath, D. Fullerton, G. Pierce, 2002, The Annals of thoracic surgery.

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020 .

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity

G. Toby, J. Sommer, G. Pierce, 2014, PloS one.

Targeted Delivery of DNA Encoding Cytotoxic Proteins through High-Affinity Fibroblast Growth Factor Receptors

M. Black, L. Chandler, G. Pierce, 1998 .

Effects of oxygen on wound responses to growth factors: Kaposi's FGF, but not basic FGF stimulates repair in ischemic wounds.

D. Ladin, Thomas A. Mustoe, MD, FACS, G. Pierce, 1995, Growth factors.

Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity.

K. Miyazono, C. Heldin, J. Waltenberger, 1992, Biochemical and biophysical research communications.

Actions of platelet‐derived growth factor isoforms in mesangial cells

H. Abboud, G. Grandaliano, M. Pinzani, 1994, Journal of cellular physiology.

Keratinocyte growth factor causes proliferation of urothelium in vivo.

D. Lacey, D. Danilenko, A. Shabaik, 1995, The Journal of urology.

Monomeric Fc Fusion Technology: An Approach to Create Long‐Lasting Clotting Factors

A. Bitonti, J. Dumont, G. Pierce, 2012 .

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein

A. Bitonti, G. Toby, G. Pierce, 2013, Journal of thrombosis and haemostasis : JTH.

Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.

K. Fischer, J. Mahlangu, B. Nolan, 2017, The Lancet. Haematology.

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

A. Bitonti, J. Dumont, L. Valentino, 2012, Blood.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

J. Mahlangu, R. Liesner, B. Nolan, 2015, Journal of thrombosis and haemostasis : JTH.

The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.

R. Sarkar, Juan Li, Xiao Xiao, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract.

R. Whitehead, G. Pierce, J. Tarpley, 1994, The Journal of clinical investigation.

Keratinocyte growth factor induces pancreatic ductal epithelial proliferation.

T. Ulich, G. Pierce, S. L. Aukerman, 1994, The American journal of pathology.

Acceleration of tissue repair by transforming growth factor beta 1: identification of in vivo mechanism of action with radiotherapy-induced specific healing deficits.

D. Cromack, J. Purdy, Thomas A. Mustoe, MD, FACS, 1993, Surgery.

Antiinflammatory effects of polypeptide growth factors. Platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor inhibit the cytokine-induced expression of the alternative complement pathway activator factor B in human fibroblasts.

R. Strunk, G. Pierce, A. Circolo, 1990, The Journal of biological chemistry.

Results of Genetic Analysis of 11,341 Participants Enrolled in the My Life, Our Future (MLOF) Hemophilia Genotyping Initiative

J. Shendure, Martin Kircher, B. Martin, 2020 .

Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: differential action on incisional wound healing.

Thomas A. Mustoe, MD, FACS, G. Pierce, R. Jyung, 1994, Surgery.

Quantitative analysis of inflammatory cell influx, procollagen type I synthesis, and collagen cross-linking in incisional wounds: influence of PDGF-BB and TGF-beta 1 therapy.

Thomas A. Mustoe, MD, FACS, D. Brown, G. Pierce, 1991, The Journal of laboratory and clinical medicine.

Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

V. Haurigot, H. Stedman, J. F. Wright, 2010, Blood.

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

M. Ozelo, D. Quon, A. Leavitt, 2022, The New England journal of medicine.

Adeno-associated virus (AAV)–mediated gene therapy is under investigation as a thera- peutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ

M. Laffan, K. Pasi, S. Rangarajan, 2019 .

Keratinocyte growth factor causes cystic dilation of the mammary glands of mice. Interactions of keratinocyte growth factor, estrogen, and progesterone in vivo.

G. Pierce, J. Tarpley, S. L. Aukerman, 1994, The American journal of pathology.

Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor.

R. Cardiff, E. Yi, T. Ulich, 1994, The American journal of pathology.

Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft.

D. Ku, A. Lumsden, S. Hanson, 1996, Circulation.

Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein

J. Dumont, K. Kobayashi, G. Pierce, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

AAV5–Factor VIII Gene Transfer in Severe Hemophilia A

D. Perry, M. Laffan, S. Rangarajan, 2017, The New England journal of medicine.

Activity of Transgene-Produced B-Domain Deleted Factor VIII in Human Plasma Following AAV5 Gene Therapy.

K. Pasi, S. Rangarajan, G. Pierce, 2020, Blood.

Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?

M. Skinner, R. Kaczmarek, G. Pierce, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector

D. Curiel, D. Buchsbaum, B. Rogers, 1998 .

First‐year results of an expanded humanitarian aid programme for haemophilia in resource‐constrained countries

F. Peyvandi, H. M. van den Berg, G. Pierce, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.

G. Pierce, Haiyan Jiang, J. Kulman, 2015, Thrombosis research.

Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways

D. Lacey, G. Pierce, J. Doukas, 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

De novo generation of permanent neovascularized soft tissue appendages by platelet-derived growth factor.

C. Serdar, G. Pierce, J. Tarpley, 1994, The Journal of clinical investigation.

Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats.

D. Lacey, J. Lakshmanan, S. Soltani, 1996, Gastroenterology.

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

J. F. Wright, K. High, V. Arruda, 2007, Blood.

Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study

T. Matsushita, K. Nogami, M. Taki, 2016 .

Ultrastructural localization of a platelet-derived growth factor/v-sis-related protein(s) in cytoplasm and nucleus of simian sarcoma virus-transformed cells.

H. Yeh, G. Pierce, T. Deuel, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Platelet‐derived growth factor/sis in normal and neoplastic cell growth

H. Yeh, G. Pierce, T. Deuel, 1987, Journal of cellular physiology. Supplement.

Natural cytotoxicity in immunodeficiency diseases: preservation of natural killer activity and the in vivo appearance of radioresistant killing.

G. Pierce, S. Polmar, R. U. Sorensen, 1986, Human immunology.

Impaired culture generated cytotoxicity with preservation of spontaneous natural killer-cell activity in cartilage-hair hypoplasia.

G. Pierce, S. Polmar, B. Schacter, 1983, The Journal of clinical investigation.

Platelet-derived growth factor BB induces functional vascular anastomoses in vivo.

G. Pierce, C. Farrell, R. Khouri, 1995, Proceedings of the National Academy of Sciences of the United States of America.

The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.

C. Kessler, J. Lusher, G. Pierce, 1989, JAMA.

Keratinocyte growth factor induces granulation tissue in ischemic dermal wounds. Importance of epithelial-mesenchymal cell interactions.

R. Galiano, Thomas A. Mustoe, MD, FACS, G. Pierce, 1996, Archives of surgery.

Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor.

Thomas A. Mustoe, MD, FACS, G. Pierce, P. Gramates, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Gene therapy: reality or myth for the global bleeding disorders community?

I. Verma, G. Pierce, K. Kelley, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Chick limb bud mesodermal cell chondrogenesis: inhibition by isoforms of platelet-derived growth factor and reversal by recombinant bone morphogenetic protein.

A. Reddi, V. Paralkar, G. Pierce, 1992, Experimental cell research.

Causes Cystic Dilation of the Mammary Glands of Mice

G. Pierce, J. Tarpley, S. L. Aukerman, 2007 .

Liver Gene Therapy: Reliable and Durable?

R. Herzog, G. Pierce, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories

B. Konkle, J. Sommer, G. Pierce, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Role of hypoxia in growth factor responses: differential effects of basic fibroblast growth factor and platelet‐derived growth factor in an ischemic wound model

Thomas A. Mustoe, MD, FACS, G. Pierce, J. Tarpley, 1994, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates

M. Ozelo, C. Négrier, A. Shapiro, 2015, British journal of haematology.

WFH Guidelines for the Management of Hemophilia, 3rd edition

E. Santagostino, M. Carcao, B. Feldman, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

M. Laffan, K. Pasi, S. Rangarajan, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.

J. Oldenburg, D. Perry, M. Ozelo, 2016, Thrombosis and haemostasis.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia

J. Oldenburg, D. Perry, M. Ozelo, 2017 .

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice

A. Bitonti, G. Toby, J. Sommer, 2016, PloS one.

Clinical haemophilia Long-term safety and efficacy of recombinant factor VIII Fc fusion protein ( rFVIIIFc ) in subjects with haemophilia

D. Perry, B. Konkle, K. Pasi, 2016 .

Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals.

J. Dumont, G. Pierce, Haiyan Jiang, 2015, Thrombosis research.

Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study

D. Perry, B. Konkle, J. Mahlangu, 2015 .

Japanese subject subpopulation analysis of B-LONG: a Phase 3 study of long-acting recombinant factor IX Fc fusion protein

T. Matsushita, M. Taki, M. Shima, 2015 .

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

J. Sommer, G. Pierce, Haiyan Jiang, 2014, Thrombosis and Haemostasis.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

J. Dumont, D. Perry, L. Valentino, 2013, The New England journal of medicine.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

L. Valentino, A. Shapiro, G. Pierce, 2013 .

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

J. Dumont, I. Nestorov, D. Perry, 2014, Blood.

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype

F. Driessler, J. Sommer, G. Pierce, 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A

D. Perry, D. Quon, J. Mahlangu, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Changes in health‐related quality of life with treatment of longer‐acting clotting factors: results in the A‐LONG and B‐LONG clinical studies

K. Wyrwich, J. Mahlangu, S. Krishnan, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

John E. Murphy, C. Pan, H. Tjandra, 2010, Blood.

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.

Ji-Yun Kim, J. Sommer, Junliang Pan, 2007, Blood.

Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP)

Kirk W. Johnson, C. Scallan, G. Pierce, 2005, Thrombosis and Haemostasis.

The World Federation of Hemophilia Annual Global Survey 1999‐2018

Jeffrey S. Stonebraker, A. Iorio, J. Stonebraker, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

M. Laffan, K. Pasi, S. Rangarajan, 2020, The New England journal of medicine.

Reimbursing the value of gene therapy care in an era of uncertainty

G. Pierce, D. Coffin, D. Noone, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Role of platelet‐derived growth factor in wound healing

Thomas A. Mustoe, MD, FACS, G. Pierce, A. Thomason, 1991, Journal of cellular biochemistry.

Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms

Thomas A. Mustoe, MD, FACS, R. Senior, G. Griffin, 1989, The Journal of cell biology.

A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.

R. Allman, P. Goode, C. Serdar, 1994, Archives of surgery.

Recombinant Human Platelet-derived Growth Factor-BB for the Treatment of Chronic Pressure Ulcers

L. Phillips, M. Robson, G. Pierce, 1992, Annals of plastic surgery.

Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair.

G F Pierce, Thomas A. Mustoe, MD, FACS, G. M. Fox, 1992, The American journal of pathology.

Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.

J. Dumont, G. Pierce, Haiyan Jiang, 2015, Thrombosis research.

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

D. Perry, B. Konkle, K. Pasi, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

C. Yanover, T. Przytycka, S. Cole, 2013, Nature Medicine.

Title Endogenous factor VIII synthesis from the intron 22-inverted F 8 locus may modulate the immunogenicity of replacement therapy for hemophilia

Yasmin, C. Yanover, T. Przytycka, 2014 .

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

L. Couto, C. Scallan, Shangzhen Zhou, 2006, Blood.

Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table

A. Weill, T. Sannié, K. Pasi, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies

A. Weill, M. Skinner, S. Pipe, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

A. Bitonti, J. Dumont, T. Nichols, 2012, Blood.

Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

C. Hermans, M. Makris, T. Sannié, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

J. Dumont, S. Qiao, W. Lencer, 2015, Critical reviews in biotechnology.

Improving access to hemophilia care in sub-Saharan Africa by capacity building.

J. Mahlangu, S. Kitchen, G. Pierce, 2019, Blood advances.

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

P. Kuebler, J. Mahlangu, S. Pipe, 2020, Journal of thrombosis and haemostasis : JTH.

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A

S. Bunting, K. Pasi, S. Fong, 2022, Nature Medicine.

World Federation of Hemophilia Gene Therapy Registry

A. Iorio, B. Konkle, B. Tortella, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

P. Kuebler, J. Mahlangu, S. Pipe, 2020, Journal of thrombosis and haemostasis : JTH.

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

G F Pierce, A. Iorio, D. Messner, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

CD8+ T-cell responses to adeno-associated virus capsid in humans

Marcela V Maus, Hildegund C J Ertl, Haiyan Jiang, 2007, Nature Medicine.

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) in Previously Treated Paediatric Subjects with Severe Haemophilia A (Kids A-LONG)

J. Mahlangu, B. Nolan, G. Young, 2013 .

Interim Analysis Of The ASPIRE Study Evaluating Long-term Safety And Efficacy Of Recombinant Factor VIII FC (RFVIIIFC) In Children With Severe Haemophilia A

J. Mahlangu, B. Nolan, G. Young, 2015 .

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

J. Mahlangu, B. Nolan, G. Young, 2014 .

603. Correction of Hemophilia B Phenotype by Novel Method of Regional Intravenous Delivery of AAV Vector to Skeletal Muscle of Hemophilia B Dogs

H. Stedman, T. Nichols, K. High, 2005 .

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

G. Pierce, Haiyan Jiang, Shuanglian Li, 2013 .

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

M. Laffan, K. Pasi, S. Rangarajan, 2020 .

Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in HemophiliaA Dogs

John E. Murphy, D. Lillicrap, A. Labelle, 2008 .

1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B

J. Rasko, M. Kay, M. Ozelo, 2004 .

World bleeding disorders registry: The pilot study

A. Iorio, D. Lillicrap, H. M. van den Berg, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

D. Perry, B. Konkle, K. Pasi, 2015 .

Multi-year Therapeutic Benefit of AAV Serotypes 2, 6 and 8 Delivering Factor VIII to Hemophilia A Mice and Dogs Running Title: Long Term Liver-specific AAV-FVIII Therapy in Dogs

Morag, L. Couto, C. Scallan, 2006 .

A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A

M. Ozelo, M. Laffan, K. Pasi, 2020 .

Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH

A. Iorio, B. Konkle, J. Mahlangu, 2020, Journal of thrombosis and haemostasis : JTH.

Monomeric Fc‐Fusion Proteins

J. Dumont, S. Krassova, G. Pierce, 2013 .

The COVID‐19 pandemic: New global challenges for the haemophilia community

A. Weill, C. Hermans, G. Pierce, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020, Blood.

Gene Therapy for Hemophilia: Are Expectations Matching Reality?

G. Pierce, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and efficacy of emicizumab and other novel agents in newborns and infants

D. Hart, R. Kaczmarek, G. Pierce, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

TGF-beta and PDGF mediated tissue repair: identifying mechanisms of action using impaired and normal models of wound healing.

D. Cromack, Thomas A. Mustoe, MD, FACS, G. Pierce, 1991, Progress in clinical and biological research.

Treatment of nonhealing diabetic foot ulcers with a platelet‐derived growth factor gene‐activated matrix (GAM501): Results of a Phase 1/2 trial

G. Mulder, L. Chandler, G. Pierce, 2009, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

L. Phillips, M. Robson, G. Pierce, 1992, The Lancet.

Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects.

A. Reddi, J. Hollinger, G. Pierce, 1993, The Journal of clinical investigation.

Growth factors and wound healing : basic science and potential clinical applications

Usa Serono Symposia, D. Herndon, T. Ziegler, 1997 .

Collagen-embedded platelet-derived growth factor DNA plasmid promotes wound healing in a dermal ulcer model.

G F Pierce, Thomas A. Mustoe, MD, FACS, L. Chandler, 2000, The Journal of surgical research.

Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.

D. Lacey, K. Rex, C. Potten, 1998, Cancer research.

Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines

L. Chandler, G. Pierce, A. Baird, 1999, International journal of cancer.

Inflammation in nonhealing diabetic wounds: the space-time continuum does matter.

G. Pierce, 2001, The American journal of pathology.

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors.

G. Pierce, S. L. Aukerman, M. Cunningham, 2000, Human gene therapy.

Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage

G F Pierce, R. Ladner, P. Kassner, 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Boundary layer infusion of basic fibroblast growth factor accelerates intimal hyperplasia in endarterectomized canine artery.

J. Li, A. Lumsden, S. Hanson, 1997, The Journal of surgical research.

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

J. Sommer, K. High, L. Couto, 2006, Blood.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

J. Sommer, L. Couto, C. Scallan, 2006, Blood.

Effects of transient immunosuppression on adeno associated virus- mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy Running Title: Immunosuppression in AAV8-hFIX treated macaques

J. Sommer, K. High, L. Couto, 2006 .

Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties

C. Scallan, Shangzhen Zhou, P. Colosi, 2005, Journal of Virology.

Erratum: CORRIGENDUM: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

M. Kay, M. Ozelo, J. F. Wright, 2006 .

Cartilage hair hypoplasia: immunological aspects and their clinical implications.

G. Pierce, S. Polmar, 1986, Clinical immunology and immunopathology.

Immunologic studies of cartilage-hair hypoplasia in the Amish.

V. McKusick, J. Winkelstein, C. Francomano, 1981, The Johns Hopkins medical journal.

Lymphocyte dysfunction in cartilage-hair hypoplasia: evidence for an intrinsic defect in cellular proliferation.

G. Pierce, S. Polmar, 1982, Journal of immunology.

ERRATUM: People to watch

J. Rasko, M. Kay, J. Zehnder, 2006, Nature Medicine.

Staphylococcus aureus Cowan I-induced immunoglobulin production in human cord blood lymphocytes.

G. Pierce, R. Sorensen, S. Polmar, 1980, Journal of immunology.

Neu differentiation factor upregulates epidermal migration and integrin expression in excisional wounds.

G F Pierce, G. Pierce, J. Tarpley, 1995, The Journal of clinical investigation.

Targeting bacteriophage to mammalian cell surface receptors for gene delivery.

G. Pierce, A. Baird, D. Larocca, 1998, Human gene therapy.

Lymphocyte dysfunction in cartilage hair hypoplasia. II. Evidence for a cell cycle specific defect in T cell growth.

G. Pierce, S. Polmar, 1982, Clinical and Experimental Immunology.

Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.

G F Pierce, G P Siegal, D. Curiel, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells

C. Miller, D. Curiel, P. Reynolds, 1998 .

Pharmacogenetics and the immunogenicity of protein therapeutics

C. Yanover, Z. Sauna, G. Pierce, 2011, Nature Biotechnology.

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice.

D. Curiel, G. Pierce, J. Doukas, 1999, Cancer research.

Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand.

G. Pierce, J. Doukas, B. Sosnowski, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Differential acceleration of healing of surgical incisions in the rabbit gastrointestinal tract by platelet-derived growth factor and transforming growth factor, type beta.

D. Cromack, Thomas A. Mustoe, MD, FACS, G. Pierce, 1990, Surgery.

FGF2-targeted adenoviral vectors for systemic and local disease.

G. Pierce, J. Doukas, B. Sosnowski, 1999, Current opinion in molecular therapeutics.

Fibroblast growth factor-2-toxin induced cytotoxicity: differential sensitivity of co-cultured vascular smooth muscle cells and endothelial cells.

P. Lin, H. Greisler, G. Pierce, 1998, Atherosclerosis.

Matrix‐enabled gene transfer for cutaneous wound repair

L. Chandler, G. Pierce, J. Doukas, 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Targeting DNA to Cells with Basic Fibroblast Growth Factor (FGF2)*

Y. Buechler, L. Chandler, G. Pierce, 1996, The Journal of Biological Chemistry.

Role of platelet‐derived growth factor in osteoblast function and bone synthesis

G. Pierce, D. Goodkin, 1993, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

D. Perry, L. Valentino, M. Ozelo, 2013 .

Cytotoxic effects of basic FGF and heparin binding EGF conjugated with cytotoxin saporin on vascular cell cultures.

J. Li, A. Lumsden, G. Pierce, 1998, The Journal of surgical research.

Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5.

P. Campochiaro, S. Kachi, Kris Jones, 2006, Virology.

Roles of Keratinocyte Growth Factor in Epithelial Growth and Regeneration

J. Rubin, G. Pierce, S. L. Aukerman, 1997 .

Transforming growth factor /3 reverses the glucocorticoid-induced wound-healing deficit in rats: Possible regulation in macrophages by platelet-derived growth factor

Thomas A. Mustoe, MD, FACS, G. Pierce, Jane LINGELBACHt, 2022 .

The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.

S. Ross, T. Burgess, G. Pierce, 1995, Proceedings of the National Academy of Sciences of the United States of America.